22nd Century Group’s CEO James Mish joined me recently on on The Green Peak. With a strong background in synthetic cannabinoid API’s and in the traditional Pharmaceutical industry, this made for an interesting discussion.
James was appointed Chief Executive Officer of 22nd Century Group in June 2020. He has an outstanding track record of delivering profitable growth at both privately held and publicly-traded science-driven companies with a focus on pharmaceutical and consumer product commercialization.
Prior to joining the 22nd Century, he served as President and Chief Executive Officer of Purisys, a synthetic cannabinoid API, ingredients and solutions provider to pharmaceutical and consumer products companies, and Noramco, a global leader in the production of controlled substances for the pharmaceutical industry.
At Noramco, he led the private equity carve-out of Noramco from Johnson & Johnson/Janssen Pharmaceuticals and spearheaded the subsequent creation and spinoff of Purisys from Noramco. Mr. Mish began his career at Pfizer in research and development before holding positions of increasing responsibility at several companies including as President of Ashland Specialty Ingredients – Consumer Specialties, a major division of Ashland Corporation, a premier, global specialty materials company serving customers in a wide range of consumer and industrial markets.